Guardant Health
GH48
$23.73arrow_drop_down2.46%-$0.60
GH48
$23.73
arrow_drop_down2.46%Performance History
| Key Stats | |
|---|---|
| Open | $24.43 |
| Prev. Close | $24.35 |
| EPS | -4.11 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| PE Ratio | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 23.94 | 24.58 |
| 52 Week Range | 15.81 | 37.66 |
| Ratios | |
|---|---|
| EPS | -4.11 |
Score Breakdown
Welcome to Stocklytics
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Analyst Forecast
Period: Next 12 Months
•Analyst Ratings
••
About Guardant Health (GH)
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- CEO
- Dr. Helmy Eltoukhy Ph.D.
- Headquarters
- Palo Alto
- Employees
- 1793
- Exchange
- NASDAQ
Keep an eye on Guardant Health
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
help
What is Guardant Health 's (GH) price per share?
The current price per share for Guardant Health (GH) is $23.73. The stock has seen a price change of -$0.6 recently, indicating a -2.47% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for Guardant Health (GH)?
For Guardant Health (GH), the 52-week high is $37.04, which is 56.09% from the current price. The 52-week low is $15.81, the current price is 50.09% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is Guardant Health (GH) a growth stock?
Guardant Health (GH) has shown an average price growth of 0.41% over the past three years. It has received a score of 8 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Guardant Health as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is Guardant Health (GH) stock price performance year to date (YTD)?
As of the latest data, Guardant Health (GH) has a year-to-date price change of -10.49%. Over the past month, the stock has experienced a price change of -26.21%. Over the last three months, the change has been -18.23%. Over the past six months, the figure is 28.55%. Looking at a longer horizon, the five-year price change stands at -70.9%.
help
Is Guardant Health (GH) a profitable company?
Guardant Health (GH) has a net income of -$479.45M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 59.74% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -56.6% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $563.95M, with a revenue growth rate of 25.45%, providing insight into the company's sales performance and growth. The gross profit is $336.9M. Operating income is noted at -$562.52M. Furthermore, the EBITDA is -$382.2M.
help
What is the market capitalization of Guardant Health (GH)?
Guardant Health (GH) has a market capitalization of $3B. The average daily trading volume is 2.58M, indicating the stock's liquidity and investor engagement.
News
GUARDANT HEALTH
STOCK OFFERING
CASH BURN
PROFITABILITY
8/26/2024Why Guardant Health Stock Just Crashed 10%
LABORATORY-DEVELOPED TESTS
LDTS
FDA REGULATIONS
CLINICAL LABORATORIES
DIAGNOSTIC SERVICES
DIAGNOSTIC PRODUCTS
8/15/2024Laboratory-Developed Tests (LDTs) World Market Forecast Report to 2028, with Coverage of the Effects of the FDA's New "Medical Devices: Laboratory Developed Tests" Rule, Passed in April 2024
AMAZON
ROKU
GUARDANT HEALTH
CATHIE WOOD
ARK INVEST
8/12/2024Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
CATHIE WOOD
ARK INVEST
GUARDANT HEALTH
OKLO
CRISPR THERAPEUTICS
7/31/2024Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
ARK INVEST
TESLA
AUTONOMOUS TAXI
7/19/2024Cathie Wood-Led Ark Invest Sells $8M In Tesla Shares Despite Bullish Autonomy Forecast - Benzinga
ANALYST RATINGS
6/28/2024Where Guardant Health Stands With Analysts